Testing an Inflammation Treatment for Heart Failure
Treatments studied
Part of Heart & circulation, Immune system & allergy clinical trials.
This early-stage trial tests a new approach to treat heart failure with preserved ejection fraction (HFpEF)—a type of heart failure where the heart's pumping strength is normal, but it doesn't relax properly. Researchers believe inflammation plays a role and want to see if targeting it can help patients feel better and function more easily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with heart failure with preserved ejection fraction (HFpEF)
- Your kidneys are working reasonably well (no significant kidney disease or renal insufficiency)
- You are willing to participate in an early-stage research study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
This study looks at whether fat around the heart affects a type of heart failure where the heart pumps well but is stiff (HFpEF). You may be able to join if you have this condition, are 18 or older, and can understand English.
This study tests whether giving intravenous iron improves symptoms, quality of life, and exercise ability in people with heart failure and low iron levels. Participants will receive iron infusions and be monitored over time to see if their condition improves.
This trial studies people who have heart failure symptoms but whose heart pumping strength is largely preserved. It aims to better understand this specific type of heart failure and how best to treat or evaluate it.
This study looks for people who may have a type of heart failure where the heart pumps normally but still doesn't work well. It aims to better understand who gets this condition and how to spot it earlier.
This study tests an investigational medication called elecoglipron to see if it can improve heart and blood vessel outcomes in people with heart failure with preserved or mildly reduced ejection fraction. If you join, you will receive either the study drug or a placebo, and your heart health will be monitored over time.
Hear when a new Heart Failure With Preserved Ejection Fraction (HFPEF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.